These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2890665)

  • 41. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats.
    Barone FC; Nelson AH; Ohlstein EH; Willette RN; Sealey JE; Laragh JH; Campbell WG; Feuerstein GZ
    J Pharmacol Exp Ther; 1996 Nov; 279(2):948-55. PubMed ID: 8930204
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension.
    Bauer IH; Reams GP; Wu Z; Lau-Sieckman A
    J Hum Hypertens; 1995 Apr; 9(4):237-43. PubMed ID: 7595905
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Some aspects of kidney function, the renin-aldosterone system and sympathetic activity in essential hypertension.
    Pedersen EB
    Acta Med Scand Suppl; 1980; 636():1-66. PubMed ID: 6103641
    [No Abstract]   [Full Text] [Related]  

  • 44. Rapid identification of patients with essential hypertension sensitive to acebutolol (a new cardioselective beta-blocker).
    Menard J; Bertagna X; N'Guyen PT; Degoulet P; Corvol P
    Am J Med; 1976 May; 60(6):886-90. PubMed ID: 14503
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Betaxolol hydrochloride in the treatment of mild and medium hypertension--long-term effects].
    Soucek M; Julínek J; Rihácek I; Stejfa M
    Vnitr Lek; 1995 Sep; 41(9):605-8. PubMed ID: 7483351
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension.
    Mahmud A; Feely J
    Am J Hypertens; 2005 Jan; 18(1):50-5. PubMed ID: 15691617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bucindolol, a beta-adrenoceptor blocker with vasodilatory action: its effect in systemic hypertension.
    Rotmensch HH; Rocci ML; Vlasses PH; Swanson BN; Fedder IL; Soyka L; Ferguson RK
    Am J Cardiol; 1984 Aug; 54(3):353-6. PubMed ID: 6147080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Changes in hemodynamics and renal function during the oral administration of betaxolol].
    Pathe M; Schwartz J
    Therapie; 1985; 40(4):209-12. PubMed ID: 2862715
    [No Abstract]   [Full Text] [Related]  

  • 49. Effects of nitrendipine on blood pressure, renin-angiotensin system, and kidney function in essential hypertension.
    Glorioso N; Manunta P; Troffa C; Pazzola A; Soro A; Pala F; Melis MG; Madeddu P; Tonolo G
    J Cardiovasc Pharmacol; 1988; 12 Suppl 4():S142-5. PubMed ID: 2468859
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Betaxolol treatment of hypertension in postmenopausal women].
    Bystrova MM; Britov AN; Gorbunov VM; Lebedev AV; Eliseeva NA; Metel'skaia VA
    Ter Arkh; 1999; 71(6):67-9. PubMed ID: 10420462
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Antihypertensive effect of betaxolol at increasing doses].
    Pathe M; Steimer C; Schwartz J
    Therapie; 1982; 37(1):75-82. PubMed ID: 6124052
    [No Abstract]   [Full Text] [Related]  

  • 52. [Pharmacodynamic effects of lokren (betaxolol) in 3 month treatment of blood hypertension in elderly patients].
    Lazebnik LB; Komissarenko IA; Guseĭnzade M; Shakurova MIu
    Ter Arkh; 1998; 70(6):44-7. PubMed ID: 9695226
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients.
    Gross E; Rothstein M; Dombek S; Juknis HI
    Am J Kidney Dis; 2005 Jul; 46(1):94-101. PubMed ID: 15983962
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preserved renal perfusion during treatment of essential hypertension with the beta blocker nadolol.
    O'Connor DT; Barg AP; Duchin KL
    J Clin Pharmacol; 1982 Apr; 22(4):187-95. PubMed ID: 6124557
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nifedipine and arotinolol in combination for accelerated-malignant hypertension: results of one year follow-up.
    Nakamoto H; Nemoto H; Sugahara S; Okada H; Suzuki H
    Hypertens Res; 1999 Jul; 22(2):75-80. PubMed ID: 10487322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of nadolol in treatment of hypertension.
    Volicer L; Liang CS; Gavras H; Tifft CP; Kershaw GR; Gavras I; Griffith DL; Vukovitch R; Brunner HR
    J Clin Pharmacol; 1979; 19(2-3):137-47. PubMed ID: 33998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antihypertensive and humoral effects of nifedipine in essential hypertension uncontrolled by hydrochlorothiazide alone.
    Opsahl JA; Halstenson CE; Abraham PA
    Am J Hypertens; 1989 Nov; 2(11 Pt 1):828-33. PubMed ID: 2686710
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system.
    Schmidt BM; Georgens AC; Martin N; Tillmann HC; Feuring M; Christ M; Wehling M
    J Clin Endocrinol Metab; 2001 Feb; 86(2):761-7. PubMed ID: 11158043
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systemic and renal hemodynamic effects of celiprolol in essential hypertensives.
    Lucarini AR; Salvetti A
    Am J Cardiol; 1988 Feb; 61(5):45C-48C. PubMed ID: 2963525
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of the calcium antagonist felodipine on the sympathetic and renin-angiotensin-aldosterone systems in essential hypertension.
    Katzman PL; Hulthén UL; Hökfelt B
    Acta Med Scand; 1988; 223(2):125-31. PubMed ID: 3279724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.